AFAndrey Finegersh

Andrey Finegersh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrey Finegersh has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Beers Criteria Medications in Elderly Patients With Head and Neck Cancer

    by Maxwell Y. Lee, Mason M. Sakamoto, Dale Kim, Andrey Finegersh, Vasu Divi, Rosh K. V. Sethi, Michelle M. Chen

    Background: Head and neck cancer patients often experience polypharmacy due to complex treatments and comorbidities. The Beers Criteria is a list of potentially inappropriate medications (PIMs) for patients above age 65 developed by the American Geriatrics Society. We hypothesize that increased use of PIMs will be associated with inferior health and quality of life outcomes in elderly patients with head and neck cancer. Methods: We retrospectively examined patients aged ≥ 65 years with head and neck cancer diagnosed between 2011 and 2015 using SEER‐Medicare data, analyzing associations between Beers Criteria Medications (BCMs) and survival as a primary outcome. Emergency department (ED) utilization served as a secondary outcome. Results: Among 5213 patients (mean age 72.6 years), 44% received no BCMs within 1 year of diagnosis, while 41.3% received 1 BCM, 9.3% received 2 BCMs, and 5.4% received ≥ 3 BCMs. The most common medications prescribed were Lorazepam (12.3%), Zolpidem (7.9%), and Alprazolam (7.5%). Two‐year survival decreased with BCM use in a dose‐dependent fashion: 88.2% (0 BCM), 86.8% (1 BCM), 86.7% (2 BCMs), and 81.4% (≥ 3 BCMs; p < 0.001). BCM users had higher ED utilization in the year after diagnosis (mean 1.21 vs. 0.95 claims, p = 0.004). Conclusions: BCMs in elderly head and neck cancer patients were associated with inferior survival and increased healthcare utilization. These findings highlight the need for medication reconciliation and systematic reviews by multidisciplinary care teams to optimize outcomes in this vulnerable population.

  • Antibiotic Use and Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma

    by Shannon S. Wu, Vasu Divi, John B. Sunwoo, Anushka Jetly, Fangdi Sun, A. Dimitrios Colevas, F. Chris Holsinger, Jake Lee, Andrey Finegersh, Fred Baik, et al.

    Background: The clinical relevance of antibiotic exposure on immune checkpoint inhibitor (ICI) efficacy in head and neck squamous cell carcinoma (HNSCC) is not well characterized. Methods: This retrospective study included patients with recurrent/metastatic HNSCC treated between 2015 and 2025. Cox proportional hazards and Kaplan–Meier method modeled overall survival (OS). Results: Of 316 patients (median age 68 years, 70.9% male), primary tumor site was 40.5% oral cavity, 34.8% oropharynx, 14.9% sinonasal/nasopharynx, 9.8% hypopharynx/larynx. One hundred and forty‐eight (46.8%) patients received antibiotics surrounding ICI. Antibiotics were associated with decreased OS (HR = 1.53, 95% CI 1.15–2.04). On multivariable analysis, while intravenous route of administration and spectrum of antibiotic activity were not risk factors, oral cavity site (HR = 1.72, 95% CI 1.07–2.76), ECOG 2–4 (HR = 2.78, 95% CI 1.70–3.67), PD‐L1 CPS < 1 (HR = 3.16, 95% CI 1.79–5.04), and number of antibiotic classes (HR = 1.37, 95% CI 1.18–1.59) independently predicted decreased OS. Conclusions: Antibiotic exposure was associated with decreased survival in HNSCC treated with ICI; however, future studies are needed to evaluate potential mechanistic etiologies underlying this association.


  • Cost Comparison of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection in Early‐Stage Oral Cavity Squamous Cell Carcinoma

    by Shannon S. Wu, Noel F. Ayoub, Michelle M. Chen, Andrey Finegersh, John B. Sunwoo, F. Chris Holsinger, Vasu Divi, Fred M. Baik

    Background: Elective neck dissection (END) is the standard treatment for early‐stage oral cavity squamous cell carcinoma (OCSCC). This study compared costs of sentinel lymph node biopsy (SLNB) and END from the Medicare payer perspective. Methods: Thirty‐two patients with T1‐2N0M0 OCSCC (16 SLNB and 16 END) treated at an academic institution from 2017 to 2025 were included. Results: 32 patients were included: median age 62, 46.9% male, 38% had adjuvant RT. The SLNB cohort had shorter operative time and length‐of‐stay. Four patients had reoperations: 2 after SLNB (completion neck dissection, tumor re‐resection) and 2 after END (neck hematomas). The SLNB cohort had lower costs for postoperative admission ($9567 vs. $12 920, p = 0.015). Total costs were not statistically different ($19 777 vs. $22 126, p = 0.45). On break‐even analysis, SLNB with a completion ND rate ≤ 35% had lower costs than END. Conclusions: Costs of SLNB were 10.6% less than END, and remained lower with completion ND rates ≤ 35%.

  • Factors Associated With Psychological Distress Among Thyroid Cancer Patients

    by Matthew E. Lin, Eric X. Wei, Andrey Finegersh, Lisa A. Orloff, Julia E. Noel, Michelle M. Chen

    Objective: To assess the prevalence of psychological distress (PD) among thyroid cancer patients (TCPs) and identify clinical, demographic, and socioeconomic factors associated with PD.Study Design: Retrospective population‐based cohort study.Setting: 2016 to 2018 National Health Interview Survey.Methods: Adults with cancer were included. The primary outcome measure was moderate‐to‐severe psychological distress (MSPD), defined as a respondent score ≥5 on the validated K6 Psychological Distress Scale. χ2 tests were used to assess differences in MSPD by cancer type. Weighted multivariable logistic regression was used to elucidate factors associated with MSPD among TCPs.Results: The majority of TCPs (n = 684,674) were white (75.4%), female (78.5%), and on average 55.65 years old (SD = 13.2). 28.4% reported MSPD. On weighted analysis, TCPs were more likely to have MSPD than prostate (14.9%, P < .001), bladder (16.4%, P = .011), and nonmelanoma skin cancer (16.3%, P < .001) patients but less likely than pancreatic cancer (30.0%, P = .030) patients. TCPs who were older when surveyed (odds ratio [OR], 0.93; 95% confidence interval [CI, 0.88‐0.98), previously drank alcohol (OR, 0.23; 95% CI, 0.06‐0.91), and saw a general physician (GP) in the past year (OR, 0.14; 95% CI, 0.03‐0.56) were less likely to have MSPD. Female sex (OR, 8.12; 95% CI, 1.61‐40.89), increased number of medical comorbidities (OR, 1.46; 95% CI, 1.00‐2.14), and functional limitations (OR, 4.55; 95% CI, 1.33‐15.74) were associated with increased likelihood of MSPD.Conclusion: Nearly 30% of TCPs have MSPD, especially younger patients who do not regularly see GPs. Future work to identify the most at‐risk patients is needed to improve prevention and develop meaningful psychosocial interventions.


  • Open Access

    Suture Stenting After Sialendoscopy: A Novel Technique That Reduces Risk of Recurrent Parotitis

    by Andrey Finegersh, Julia Chang, Yu‐Jin Lee, Davud Sirjani

    Objective: Chronic sialadenitis is associated with decreased quality of life and recurrent infections. While sialendoscopy with stenting is effective in relieving symptoms of sialadenitis, currently available stents are rigid and poorly tolerated by patients, leading to early removal and potential for adverse scarring. This study examines whether sutures can be used as a stenting material to improve patient comfort and reduce recurrence risk. Methods: This is a retrospective cohort study of a consecutive series of adult patients with chronic sialadenitis undergoing sialendoscopy with or without suture stenting. Data were collected between 2014 and 2018 with a 3-year follow-up period ending in 2021. The primary outcome measure was recurrence of sialadenitis within 3 years of surgery. Secondary outcomes were stent dislodgement and patient-reported discomfort. Results: We included 63 patients with parotid sialadenitis of whom 28 underwent suture stenting and 35 did not receive stenting after sialendoscopy. Stents were well tolerated, with a mean duration of 34.5 days, and only 2 of 28 stents (7.1%) accidentally dislodged within the first week. Suture stenting significantly reduced symptom recurrence after sialendoscopy (OR = 0.09, 95% CI 0.02-0.45, p = 0.003; 3-year sialadenitis recurrence rate: 7.1% vs. 45.7%, p = 0.005). Cox multivariate regression for clinicodemographic variables showed an HR of 0.04 (95% CI 0.01-0.19, p < 0.001) for the risk of symptom recurrence. Conclusions and relevance: Suture stenting after sialendoscopy is low cost, available across all institutions, well-tolerated by patients, and highly efficacious in reducing risk of recurrent sialadenitis after sialendoscopy.